OMER earnings call for the period ending March 31, 2019.
News & Analysis: Omeros
OMER earnings call for the period ending December 31, 2018.
The small biotech received good news from the FDA.
The struggling drug developer reported third-quarter 2018 operating results and raised $210 million in debt.
It appears that an unproven approach to treating rare blood disorders will remain that way.
Investors are picking up the pieces after the biotech's bad news on Monday.
Pending clinical trial results could change the way investors feel about these biotech stocks before the leaves start falling.
Find out which of these stocks was pressured by cryptocurrency fluctuations.
Pipeline progress outlined during the company's first-quarter report lifted spirits.
Learn how these stocks kept from falling with the market.